INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Idag, 16:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
PR Newswire
NEW YORK, Nov. 20, 2025
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On November 3, 2025 , Sarepta disclosed that its late-stage ESSENCE trial for two gene therapies, AMONDYS 45 (casimersen) and VYONDYS 5 (golodirsen), both aimed at treating Duchenne muscular dystrophy, "did not meet statistical significance on its primary endpoint".
On this news, Sarepta's stock price fell $8.25 per share, or 33.74%, to close at $16.20 per share on November 4, 2025 .
Pomerantz LLP, with offices in New York , Chicago , Los Angeles , London , Paris , and Tel Aviv , is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz , known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud , breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com .
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
Ämnen i artikeln
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Idag, 16:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
PR Newswire
NEW YORK, Nov. 20, 2025
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On November 3, 2025 , Sarepta disclosed that its late-stage ESSENCE trial for two gene therapies, AMONDYS 45 (casimersen) and VYONDYS 5 (golodirsen), both aimed at treating Duchenne muscular dystrophy, "did not meet statistical significance on its primary endpoint".
On this news, Sarepta's stock price fell $8.25 per share, or 33.74%, to close at $16.20 per share on November 4, 2025 .
Pomerantz LLP, with offices in New York , Chicago , Los Angeles , London , Paris , and Tel Aviv , is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz , known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud , breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com .
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
Ämnen i artikeln
Börsuppgångarna
Asmodee
Aktieråd
Analyser
Intellego
.jpg&w=3840&q=75)
18 november, 13:44
Sparekonom: "Oerhört beklagligt för de som äger Intellego"
Börsuppgångarna
Mest läst
Asmodee
Aktieråd
Analyser
Intellego
18 november, 13:44
Sparekonom: "Oerhört beklagligt för de som äger Intellego"
Marknadsöversikt
1 DAG %
Senast
1 mån
